Acute Repetitive Seizures Market by Products (USL-261, NRL-1, AZ-002, and Diastat Rectal Gel) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global acute repetitive seizures market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the unmet clinical needs for patients and caregivers as well as the availability of an advanced product pipeline.

Acute repetitive seizures (ARS), also known as cluster seizures, refers to a condition of neurologic emergency due to the rapid occurrence of epilepsy type seizures. ARS is mostly a result of neuronal injury that normally requires hospitalization and constant care as it can easily turn out to be a life-threatening condition. Adoption of effective health management and appropriate treatment are often recommended by doctors to prevent from dire consequence of patients. In general, ARS is quite similar with epilepsy, which is a brain disorder characterized by constant seizures due to imbalanced electrical rhythms of the brain. As a consequence of this imbalanced outburst of brain’s electric energy, the consciousness, sensation, and behaviour of patients are completely disturbed. Thus, normal movements of patients are seriously affected due to this disorder.

With the wide prevalence of the disorder, the demand for effective treatment method and techniques is rising rapidly across the globe. However, the treatment gap is an obvious feature that presents a key aspect of the overall market development and is a useful metric for comparing access to quality care for seizure patients. As per several reports, the treatment gap is approximately 80% in low- and middle-income countries such as India, South Africa, and Brazil, and approximately 60% in developed countries such as the US and the UK. It is widely reported in many studies that patients usually prefer the intranasal route over other types of medicine administration routes such as buccal, rectal, and intramuscular for the treatment procedures. Meanwhile, it is considered that outpatient treatment with parenteral medications has proven to be the best option. Caregivers in some countries such as the Netherlands are not qualified to administer parenteral medications.

Market Trends, Drivers, Restraints, and Opportunities

• Wide number of ARS patients across the globe and rising healthcare spending for extreme health conditions especially neurological disorders are expected to propel the market growth during the forecast period.
• Improving in the availability of treatment drugs and introduction of innovative therapeutic methods for the disorder are projected to drive the market expansion during the forecast period.
• Reducing healthcare costs due to wide participation of governments’ agencies and their initiatives for awareness programs for the disorder present key driving factors for the market expansion.
• Strict regulation in terms of approval of drugs for the treatment and concerning issues for adverse reaction of the drug therapy act as major challenges that can hamper the market expansion.
• Rapid development of outpatient care models such as clinics and home healthcare along with rising implementation of healthcare reforms in emerging economies are expected to offer lucrative opportunities for the growth of the market in the coming years.

Scope of the Report

The report on the global acute repetitive seizures market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

USL-261 segment is expected to expand at a rapid pace

Based on products, the acute repetitive seizures market is segregated into USL-261, NRL-1, AZ-002, and diastat rectal gel. The NRL-1 segment is expected to constitute a key share of the market during the forecast period as the product is widely adopted for the treatment among children and adults. NRL-1 is an investigational drug developed by Neurelis for the use in children, adolescents, and adults. However, the USL-261 segment is anticipated to expand at a rapid pace during the forecast period owing to unique design of product for intranasal administration for outpatient use. Meanwhile, the Diastat Rectal Gel segment held a key market share in 2019 due to its efficacy in the treatment of the disorder. It was approved by the US Food and Drug Administration as an approved medication and generic versions, which were introduced in 2010.

Europe is anticipated to dominate the market

On the basis of regions, the market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of Europe is anticipated to dominate the market by expanding at an impressive CAGR during the forecast period. The regional market growth can be attributed to advancements in scientific, clinical, and medical technology adopted in the treatment centers in the region. Rising disease prevalence in the region and growing government initiatives aimed at improving the quality of life, and raising awareness about the disease are the primary drivers of the market growth in this region. However, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to rising healthcare spending in developing countries such as India and China along with a significant gap in the management of ARS cases. As a result, the demand for anti-seizure medications in these emerging economies are boosting significantly away from the already saturated European and North American markets.

Segments

Segments Covered in the Report
The global acute repetitive seizures market has been segmented on the basis of

Products

• USL-261
• NRL-1
• AZ-002
• Diastat Rectal Gel

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• UCB S.A.
• Neurelis, Inc.
• Alexza Pharmaceuticals
• Bausch Health
• Pfizer Inc.
• Sanofi
• Valeant Pharmaceuticals North America LLC.
• Veriton Pharma

Competitive Landscape

Key players competing in the global acute repetitive seizures market are UCB S.A. and Neurelis, Inc.; Alexza Pharmaceuticals; Bausch Health; Pfizer Inc.; Sanofi; Valeant Pharmaceuticals North America LLC.; and Veriton Pharma. These two major players namely UCB S.A. and Neurelis, Inc. are likely to hold the major share of the global market during the forecast period due to the successful commercialization of USL-261 and VALTOCO. Widely adopted as the key pharmaceuticals products (USL-261 and VALTOCO) and have been designated as orphan drugs, the pricing of these drugs are expected to be expensive.